Company Overview and News

1
Capital One Financial Corporation (COF) CEO Richard Fairbank on Q2 2018 Results - Earnings Call Transcript

2018-07-20 seekingalpha
Capital One Financial Corporation (NYSE:COF) Q2 2018 Earnings Conference Call July 19, 2018 5:00 PM ET
COF-D COF.PRG COF.PRH COF-C COF-F COF-P COF.WS COF.PRP COF COF.PRC COF.PRD COF.PRF

1
Capital One Financial Corporation 2018 Q2 - Results - Earnings Call Slides

2018-07-20 seekingalpha
The following slide deck was published by Capital One Financial Corporation in conjunction with their 2018 Q2 earnings call.
COF-D COF.PRG COF.PRH COF-C COF-F COF-P COF.WS COF.PRP COF COF.PRC COF.PRD COF.PRF

1
Capital One Profit Surges on Strong Card Spending, Lower Losses - WSJ

2018-07-20 wsj
Capital One Financial Corp.’s second-quarter profit rose sharply as consumer card spending surged and credit losses fell.
COF-D COF.PRG COF.PRH COF-C COF-F COF-P COF.WS COF.PRP COF COF.PRC COF.PRD COF.PRF

8
Capital One Shifts Card Team as Walmart Bid Hangs in the Balance - Bloomberg

2018-07-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
COF.PRG HCS.PRB COF.PRH COF-P COF.WS COF.PRP MA COF SYF HCS COF-D HSB 0005 COF-C COF-F HSEA HSEB HSBC.PRA COF.PRC COF.PRD HSBC COF.PRF HBCYF

12
Dow snaps 5-day win streak as financials sell off - MarketWatch

2018-07-19 marketwatch
U.S. stocks closed lower on Thursday, as major indexes consolidated their gains after a five-day rally that was driven largely by optimism over the strength of corporate earnings.
COF.PRG COF.PRH PM COF-P TRV CCV CMCSA COF.WS COF.PRP CCZ COF ISRG MRSN COF-D COF-C COF-F CCV.CL MSFT COF.PRC COF.PRD CMCSK COF.PRF

63
Bank Stock Roundup: Robust Economic Data, Q2 Earnings, C, OZRK in Focus

2018-07-13 zacks
In the last five trading days, bank stocks delivered a bullish performance. While escalating trade war between the United States, China and the European Union continued to weigh on investor sentiments, strong economic data on the domestic front largely mitigated this. The latest job market data lessened the concern that the economy is in the late stage of expansion. This news resulted in rising yield on benchmark 10-year Treasury Notes.
WFCNP COF.PRG COF.PRH CMA.WS COF.WS WFC.PRL COF.PRP WFC.PRJ KEY FITBI SAM CMPWW BAC USB COF-D WFC.PRT COF-C COF-F WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY COF.PRC WFC.PRX COF.PRD WFC.PRW WFC.PRV COF.PRF BBT WFC WFC.WS BAC C COF-P CMA COF OZRK BLK FITB

6
Oppenheimer Positive on Banks Into Earnings: 4 to Buy Now

2018-07-13 247wallst
After a sparkling 2017, many of the top bank and financial institution stocks have sputtered in 2018, and with the economy improving and the prospects for interest rates to go higher, the sector may be offering investors some of the best opportunities. Another positive for the industry has been tax reform, which appears to be helping to improve credit quality, which is a huge metric for financial institutions as they are often the lenders of first choice for consumers.
COF.PRG COF.PRH COF-P SLMBP SLMAP COF.WS COF.PRP AXP COF SLM COF-D COF-C COF-F ALLY.PRA ALLY OSM COF.PRC COF.PRD ISM JSM COF.PRF

11
6 Most Important Things In Business Today

2018-07-13 247wallst
Commerce Secretary Wilbur Ross will sell all his equities after questions about conflicts of interest. According to Bloomberg:
COF.PRG COF.PRH COF-P COF.WS TWX COF.PRP COF TWC SYF WMT COF-D COF-C COF-F T AAPL COF.PRC DAL COF.PRD COF.PRF IVZ

4
PRESS DIGEST -Wall Street Journal - July 13

2018-07-13 reuters
July 13 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
COF.PRG COF.PRH FOX COF-P CCV CMCSA COF.WS TWX COF.PRP CCZ COF TWC COF-D COF-C NOC COF-F CCV.CL COF.PRC FOXA COF.PRD CMCSK COF.PRF

20
Walmart Weighs a Bid From Capital One for Credit Cards - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
COF.PRG COF.PRH C.WSA COF.WS COF.PRP COF-D COF-C C.WS.B COF-F C.WS.A C.PRP C.PRU COF.PRC COF.PRD COF.PRF C.PRS COF-P C C.PRL C.PRJ C.PRK COST COF C.PRG SYF C.PRC C.PRPCL CGBBW GPS

40
10 Billion-Dollar Stocks for Q3 and Beyond | InvestorPlace

2018-07-09 investorplace
Investment-related articles that generate the most hype frequently focus on speculative highfliers. While there’s always a time and place for that, especially if you’re in your twenties, a well-rounded portfolio should include well-capitalized industry stalwarts. These so-called billion-dollar stocks provide an extra level of confidence in uncertain times.
COF.PRG LMT RHI HD COF.PRH ABX COF-P XOM COF.WS COF.PRP COF RGR COF-D COF-C NOC SHW COF-F AMZN AAPL COF.PRC THC COF.PRD COF.PRF ABX

9
Top Analyst Upgrades and Downgrades: Baidu, Capital One, Delphi Technologies, Dunkin’ Brands, FireEye, Walgreens and More

2018-07-09 247wallst
The futures were again trading higher Monday morning. Despite concerns over the recently imposed tariffs around the world, investors and Wall Street have their attention focused on second-quarter earnings results, which will begin this week. The trend of buying the dips has not worked as well as it has in prior years, and many investors have been considering how they want their investments positioned for the longer term.
COF.PRG COF.PRH COF.WS MS.PRE COF.PRP MS.PRF MS.PRG MS.PRA DLPH COF-D COF-C COF-F FEYE MS COF.PRC BIDU COF.PRD HSY COF.PRF HSYFB COF-P COF MS.PRI BJ MS.PRK DNKN TRI

57
Bank Stock Roundup: Trade Issues Dent Investors' Confidence, WFC & Citi in Focus

2018-07-06 zacks
In the last four trading days, bank stocks put up a lackluster show. Mortgage rates declined in the week, hitting 4.52%, along with bond yields, on escalating trade issues between United States and its major trade allies. This weighed on investor sentiments. However, homeowners seeking lower rates for refinancing are turning out to be big-time gainers. Further, the benchmark 10-year Treasury yield shrunk this week as demand for safe-haven assets increased.
WFCNP COF.PRG COF.PRH RF.PRB RF.PRA FRC COF.WS WFC.PRL RF COF.PRP WFC.PRJ BAC USB COF-D FRC.PRA WFC.PRT COF-C COF-F WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN FRC.PRI FRC.PRH FRC.PRG FRC.PRF WFC.PRY 3772 WFC.PRX COF.PRC FRC.PRE COF.PRD FRC.PRD WFC.PRW FRC.PRC WFC.PRV COF.PRF FRC.PRB BBT WFC WFC.WS BAC C COF-P COF OZRK

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...